Effects of Raloxifene on Bone Mineral Density, Serum Cholesterol Concentrations, and Uterine Endometrium in Postmenopausal Women

The Use of Estrogens and Progestins and the Risk of Breast Cancer in Postmenopausal Women

1995 • 1,532 citations

The Jackknife Estimate of Variance

1981 • 1,396 citations

Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis

1996 • 997 citations

Hormone replacement therapy and endometrial cancer risk: A meta-analysis

1995 • 944 citations

The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease

1984 • 764 citations

Repeated Significance Tests on Accumulating Data

1969 • 756 citations

Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women.

1996 • 640 citations

Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats.

1994 • 614 citations

Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial

1995 • 602 citations

Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial

1994 • 531 citations

EFFECT OF CHOLESTEROL-LOWERING DIET ON MORTALITY FROM CORONARY HEART-DISEASE AND OTHER CAUSES

1972 • 497 citations

Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women

1997 • 450 citations

Identification of an Estrogen Response Element Activated by Metabolites of 17β-Estradiol and Raloxifene

1996 • 432 citations

A controlled trial of raloxifene (LY139481) HCl: Impact on bone turnover and serum lipid profile in healthy postmenopausal women

1996 • 362 citations

Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease.

1993 • 357 citations

Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: Three years of blinded therapy followed by one year of open therapy

1993 • 356 citations

Immunoassay for quantifying type I collagen degradation products in urine evaluated

1994 • 331 citations

Plasma lipoprotein levels as predictors of cardiovascular death in women

1993 • 284 citations

Measurement of serum osteocalcin with a human-specific two-site immunoradiometric assay

1992 • 193 citations

Effects of a new antiestrogen, keoxifene (LY156758), on growth of carcinogen-induced mammary tumors and on LH and prolactin levels

1983 • 177 citations

Chemoprevention of Mammary Carcinogenesis in the Rat: Combined Use of Raloxifene and 9-cis-Retinoic Acid

1996 • 172 citations

Raloxifene preserves bone strength and bone mass in ovariectomized rats.

1994 • 165 citations

The effect of the antiestrogen tamoxifen on bone mineral density in normal late postmenopausal women

1995 • 147 citations

Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis

1995 • 142 citations

Raloxifene Inhibits Aortic Accumulation of Cholesterol in Ovariectomized, Cholesterol-Fed Rabbits

1997 • 135 citations

Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease

1993 • 120 citations

Endometrial Changes with Tamoxifen: Comparison between Tamoxifen-Treated and Nontreated Asymptomatic, Postmenopausal Breast Cancer Patients

1994 • 108 citations

Raloxifene and Estrogen: Comparative Bone-Remodeling Kinetics¹

1997 • 92 citations

Raloxifene and Estrogen: Comparative Bone-Remodeling Kinetics

1997 • 66 citations

Raloxifene preserves bone strength and bone mass in ovariectomized rats

1994 • 52 citations

Consistency of jackknife variance estimators jun

1991 • 10 citations